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Medicines price components:
Manufacturing cost
 Import duties
 Taxes / VAT
 Service costs
Markups 
(importers, distributers, retailers)
Others
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PRICE
Methodology for price control of 
medicines
 Systems with incentives for generic medicines
 Cost based on expenditure
 Negotiated prices
 Retail fees
 Mandatory discounts and price reductions
 Price index
 Tender prices
 Based on cost-effectiveness analysis
 Reference pricing
 Patients’ share of costs
Reference prices
Definition: Reference pricing (RP) system means that the 
purchaser (health insurance fund etc.) decides which price 
to pay for the medicines, while the patient or other insurer 
pays the difference up to the market price.
AIMS of the RP system in Republic of Macedonia:
 Ensure access to all necessary medicines
 Ensure the best treatment for the lowest possible cost
 Stop the rise of costs for the medicines with the same 
effectiveness/safety
 Avoid the shortening of the Positive list (PL) of 
medicines
 Enable the introduction of new medicines
History of medicines prices in the 
Republic of Macedonia
Legal regulation until 2005:
 No mechanisms to control medicines price – price 
components could not be determined
 VAT - 18%, import duties - 4% for medicines from the 
EU and 1% from the former Yugoslav republics, 
undefined wholesales margins, 13% retails markups for 
medicines reimbursable by the Health Insurance Fund 
(undefined for the rest) 
 Health Insurance Fund (HIF) organized 5 tenders (2 
international) for the Positive List medicines– indirect 
method to control medicines prices in the public system
 HIF reimbursed costs only up to the level chosen by the 
tender
Tenders for supply of medicines in 
the Republic of Macedonia
Advantages
 Successful in providing lower prices of medicines where 
competition exists (generics) – average 45% decrease 
compared with the previous year
Disadvantages
 Takes a long time, manipulations are possible, difficult to 
undertake for specific medicines with no or very little 
market competition (e.g. cancer therapy)
 The prices of medicines not supplied by tenders are not 
regulated, so the prices of similar or the same medicines 
are different in different pharmacies
Consequences
 Growing support to control the prices of medicines not 
reimbursable by the HIF
Price control of medicines in the 
Republic of Macedonia
Previous legal basis
Law on Medicines and Medicinal Products 
1998 
(Official Gazette of the Republic of Macedonia 
No.21/1998) 
 Price control for medicines from the Positive 
list (no by-laws created)
Law on Health Care Insurance (Official 
Gazette of the Republic of Macedonia 
No.119/2005)
 HIF determined the reference prices of the 
reimbursable medicines and medical devices
International consultations for the 
price control of medicines 
2005:  The last international tender for the supply of 
medicines ended up
Agreement – Regulate medicines prices by reference 
pricing (RP) system
2006 – 2010: International consultation process
Health Sector Management World Bank Project: Technical 
assistance on pricing and reimbursement policy of 
medicines
Three consultants contracted: Dr. Arie Rietveld (2006), Dr. 
Stanislav Primozic (2009) and Dr. Tonci Buble (2009/10)
International consultations for the 
price control of medicines (1)
Dr. Arie Rietveld’s 2006 recommendations:
 Introduction of international reference pricing for medicines
 Set up reimbursement limit system of medicines 
 Harmonization with the EU regulation
 Information sharing and participation of all stakeholders in 
the upcoming reforms 
Results:
 Changes in the Law on Health Care Insurance in 2007
 Rules on determination of prices of medicinal products for 
human use
 New Law on Medicinal Products and Medical Devices 2007
New Law on Medicinal Products and 
Medical Devices
Official Gazette of RM No.106/2007
Articles 107 & 108 prescribe unified prices for medicines
The basic elements that comprise the price of medicines: 
 Manufacturing costs in MKD (manufacturers and 
importers are obliged to provide the manufacturing cost 
of medicines) 
 Wholesale markups
 Retail markups
Fixed markups: wholesales markups are 9-15% and retail 
markups 15-30% of medicines cost
Changes in the Law on Health Care 
Insurance
Official Gazette of RM No.36/2007
4 new articles to define reference pricing: 
 The lowest wholesale cost of medicines registered in 
the Republic of Macedonia
 Comparative analysis of the reference prices of 
medicines on the Positive list in the referent countries 
(Slovenia, Croatia, Bulgaria, Serbia)
 Criteria to determine the price of medicines is the 
average of the two lowest ratios (reference price –
GDP per capita) in the reference countries compared 
with GDP per capita in the Republic of Macedonia
using the purchasing power parity PPP methodology 
according to the World Bank final official data
 Referent prices to be determined by HIF and agreed 
by the Ministry of Health
Rules on Determination of 
Medicines Prices 2008
Official Gazette of the Republic of Macedonia No.8/2008
In accordance with the changed Law on Health Care 
insurance
Technical criteria:
 Based on PPP methodology
 On the level of comparable wholesales price 
 The lowest offered price on the last medicines tender 
 Unified wholesales price determined by the Law on 
Medicinal Products and Medical Devices
Drawbacks:
 The methodology to determine RP not clear (mixed 
methodology)
 Used terms not defined precisely
 Technical criteria not clear
New determined reference prices of 
medicines in 2008
RP adopted by the HIF Steering Committee
Determined as comparison of the lowest offered price on 
the last medicines tender and the unified wholesales prices 
according to the Medicines Law – lower price taken
 Rigid and not adapted legal regulation does not allow 
substantial modifications of some rules in compliance 
with the actual state and needs
 Changes in the law and the rules did not give the 
expected results (rationalized medicines costs and 
controlled medicines prices)
 Changes on unified medicines prices not in line with EU 
regulations
 Legal regulation shall be changed in order to make 
executive rules that elaborate new methodology with all 
technical details
International consultations for the 
price control of medicines (2)
Dr. Stanislav Primozac’s 2009 recommendations:
 The system of unified medicines prices shall be preserved 
until new RP system of standard prices is adopted.
 Law as legal basis for medicines prices determination is 
high level of decision making, rigid and not flexible for fast 
development of health care sector and the economy
 Medicines Law to be more conceptual for medicines price 
regulations, technical details to be given as executive rules
 New legal frame required in order to comply with EU rules
Results:
 Changes in the Medicines Law (Official Gazette of the 
Republic of Macedonia No.88/2010), omitted parts on 
methodology for unified medicines prices
 Opportunity to issue new rules on methodology that 
determine medicines prices
International consultations for the 
price control of medicines (3)
Dr. Tonci Buble’s 2009/2010 stands and recommendations:
 Legal frame not adapted for the rationalization of 
medicines costs
 Incomplete rules for the inclusion of medicines on PL
 Methodology on RP determination not clear enough
 No rules on price calculations based on indications and 
dosing
 No rules on price calculation for hospital medicines
 No reliable data on medicines use 
Results:
 Consensus on changes of the Law on Health Care 
Insurance (Official Gazette of the Republic of Macedonia 
No.50/2010), omitted article 63b on RP methodology
 Opportunity to develop new rules on RP criteria and 
procedures
Rules on Determination of RP criteria 
and procedures 2009
Official Gazette of the Republic of Macedonia No.158/2009 
RP Criteria:
 Reference prices in referent countries (Slovenia, Croatia, 
Bulgaria, Serbia) from defined data sources
 Average comparable medicines price 
 The level of comparable prices in line with PPP indicator 
and on the following basis:
- For medicines with no generic competition according 
to ATC classification and prices higher than average 
comparable price (>100%), average comparable price is 
multiplied by 1
- For medicines with generic competition and prices 
79,23% higher than average comparable price, average 
comparable price is multiplied by 0,7923. This coefficient is 
used for all medicines with same generic name
Current Reference Pricing 
Methodology 
 Defined reference prices for medicines that use RP 
methodology for the first time 
 For medicines where no comparable prices are available, 
prices are determined based on pharmaco-economic 
study provided by the marketing authorization holder
 When different prices are calculated for medicines with 
same safety and efficacy (therapeutically equivalent 
medicines), pharmacological therapeutic groups are 
determined and unified RP calculated based on nr. unit 
in the package, defined daily dose and medicines 
strength
 The decision made by HIF on RP determination shall be 
published in the Official Gazette of RM once the 
agreement is reached with the Ministry of Health
 RP shall be determined annually
Table 1: Prices of 20 most used medicines 
from PL in tender 2004 and in RP 2009 (1-10)
No ATC code Generic 
name-INN
Dosing 
forms
Strength Packaging Unified price Unit  reference 
price 
1 C09AA02 enalapril tablets 20 mg 20 35,93 17,14
2 C04AD03 pentoxifillin tablets 400 mg 20 70,00 63,81
3 C09AA02 enalapril tablets 10 mg 20 30,00 16,19
4 C09AA03 lisinopril tablets 20 mg 20 139,83 17,14
5 A02BA02 ranitidin tablets 150 mg 20 58,90 21,90
6 A10BB01 glibencamid tablets 5 mg 30 50,08 20,00
7 J01CR02
amoxicilline+
clavulonic 
acid tablets (875+125) mg 10 200,17 153,33
8 J01DA01 cefalexin capsules 500mg 16 53,56 85,71
9 C09AA03 lisinopril tablets 10 mg 20 150,00 16,19
10 N05BA08 bromazepam tablets 3 mg 30 18,05 18,10
Table 1: Prices of 20 most used medicines 
from PL in tender 2004 and RP 2009 (11-20)
No ATC code Generic name-
INN
Dosing forms Strength Packaging Unified price Unit  RP
11 C08DA01 verapamil Coated tablets 80 mg 50 44,07 44,76
12 C08CA01 amlodipine tablets 10 mg 20 135,08 24,76
13 C07AB03 atenolol tablets 100 mg 15 14,00 22,86
14 J01MA02 ciprofloxacine tablets 500 mg 10 52,97 30,48
15 C08CA05 nifedipine tablets 40 mg 20 213,32 18,10
16 R03DA05 aminophylline tablets 350 mg 20 49,15 53,33
17 J01CR02
amoxicilline+
clavulonic acid suspension 475 mg/5ml 70 ml 123,99 73,33
18 C09AA02 enalapril tablets 5 mg 20 26,00 15,24
19 C08DB01 diltiazem tablets 90 mg 30 64,07 60,95
20 J01DA01 cefalexin suspension 250 mg/5ml 100 ml 58,47 88,57
Table 1: Changes in prices (%) of 20 most used 
medicines from PL in tender 2004 and RP 2009
Medicine prices tender 2004 (100%) Medicine prices RP 2009 (% of 2004) Difference 04/09
35,93 (100%) 17,14 (47,7%) 52,3% ↓
70 (100%) 63,81 (91,2%) 8,8% ↓
30 (100%) 16,19 (54%) 46% ↓
139,83 (100%) 17,14 (12,6%) 87,4% ↓
58,9 (100%) 21,9 (37,2%) 62,8% ↓
50,08 (100%) 20 (39,9%) 60,1% ↓
200,17 (100%) 153,33 (76,6%) 23,4% ↓
53,56 (100%) 85,71 (160%) 60% ↑
150 (100%) 16,19 (10,8%) 99,2% ↓
18,05 (100%) 18,1 (100,3%) 3,0 ↑
44,07 (100%) 44,76 (101,6%) 1,6% ↑
135,08 (100%) 24,76 (18,3%) 81,7% ↓
14 (100%) 22,86 (163,3%) 63,3% ↑
52,97 (100%) 30,48 (57,5%) 42,5% ↓
213,32 (100%) 18,1 (8,5%) 91,5% ↓
49,15 (100%) 53,33 (108,5%) 8,5% ↑
123,99 (100%) 73,33 (59,1%) 40,9% ↓
26 (100%) 15,24 (58,6%) 41,4% ↓
64,07 (100%) 60,95 (95,1%) 4,9% ↓
58,47 (100%) 88,57 (151,5%) 51,5% ↑
Table2A/Graph1: Av. prices (MKD per
pack) in 2004 and RP 2009
Year Average Standard 
deviation
min max
2004 79,38 59,40 14,00 213,32
2009 43,09 35,91 15,24 153,33
±Std. Dev.
±Std. Err.
Mean
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Analysis of changes in prices (%) of 20 most used 
medicines from PL in tender 2004 and RP 2009
 There is a statistically significant difference in the 
average prices per pack of the 20 most used medicines 
from PL reimbursable by HIF between 2004 and 2009 
(Mann-Whitney U Test: Z = 2,164, p = 0,0304)
 Higher RP of some medicines in 2009 may be result of 
some price manipulations by the tender competitors in 
2004
 Some generic medicines were offered under much lower 
prices by the domestic industries compared with their 
prices given in 2007 when the unified prices were being 
determined
Table 3/Graph 2: Increase or dicrease in
price per pack in tender 2004 - RP 2009
Tender 2004 / 2009 Nr. (out of 20) %
Decreased price per pack 14 70
Increased price per pack 6 30
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Analysis of changes in prices (%) of 20 most used 
medicines from PL in tender 2004 and RP 2009
 Out of 20 medicines, 14 (70%) have decreased prices 
per pack between 2004 and 2009.  There is a significant 
difference between the number of medicines with 
decreased and increased prices per pack. (Student t-test: 
p = 0,0157 )
 This analysis shows the economic justifications of the 
introduction of RP system
Outcomes of introducing the 
reference pricing in R. Macedonia
 PROS: RP system generally decreases medicines 
prices, gives bigger choice to patients and doctors, 
supports the free market of medicines, saves HIF 
finances, and helps return big percent of the saved 
finances back to the HIF for other health care activities   
 CONS 1: The difference in price up to the market price 
is paid by the patients (out-of-pocket) as no additional 
health insurance exists in R. Macedonia
 CONS 2: The  difference in price is sometimes 2-3 times 
bigger than the reference price
 CONS 3: The difference in price shall be paid for many 
medicines
Recommendations on RP in the 
Republic of Macedonia
 Conclusion: The process of RP system development and 
implementation has not been completed yet.
 Recommendation 1: Harmonize national regulations on 
medicines to support selection on new medicines for PL
 Recommendation 2: Establish better relationship between 
the price of medicines and their indication and dosing
 Recommendation 3: Make calculation rules on prices of 
medicines for hospitals
 Recommendation 4: Ensure reliable Information on 
medicines use
 Recommendation 5: Introduce the procedure for 
medicines price calculations
 Recommendation 6: Make rules on medicines price 
determination in hospitals
 Recommendation 7: Improve communication between all 
stakeholders on all medicines price activities.
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